Tag: Focal Segmental Glomerulosclerosis
Monoclonal antibodies to dominate global multiple sclerosis drugs market
Dominance of the segment is likely to be attributed to the launch of new monoclonal antibody products for the treatment of multiple sclerosis, including Ofatumumab and Ublituximab, during the forecast period.....................
Indian startup develops drug for key orphan diseases, partners US firm
Oraxion Therapeutics, a spin-off from Aten Porus Lifesciences has entered into an agreement with a US-based biopharma company to license its lead asset ORX-301 for the treatment of Niemann-Pick Type C disorder and Focal Segmental Glomerulosclerosis.......................